Affordable Access

Publisher Website

CXCL16 in kidney and cardiovascular injury

Authors
Journal
Cytokine & Growth Factor Reviews
1359-6101
Publisher
Elsevier
Volume
25
Issue
3
Identifiers
DOI: 10.1016/j.cytogfr.2014.04.002
Keywords
  • Atherosclerosis
  • Chemokine
  • Chronic Kidney Disease
  • Inflammation
Disciplines
  • Medicine

Abstract

Abstract CXC chemokine ligand 16 (CXCL16) is a CXC soluble chemokine, an adhesion molecule and a cell surface scavenger receptor. CXCL16 regulates inflammation, tissue injury and fibrosis. Parenchymal renal cells, vascular wall cells, leukocytes and platelets express and/or release CXCL16 under the regulation of inflammatory mediators. CXCL16 expression is increased in experimental and human nephropathies. Targeting CXCL16 protected from experimental glomerular injury or interstitial fibrosis. Conflicting results were reported for experimental cardiovascular injury. High circulating CXCL16 levels are associated to human kidney and cardiovascular disease and urinary CXCL16 may increase in kidney injury. In conclusion, mounting evidence suggests a role of CXCL16 in kidney and cardiovascular disease. However, a better understanding is still required before exploring CXCL16 targeting in the clinic.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

CXCL16 in kidney and cardiovascular injury

on Cytokine & Growth Factor Revie...

[The role of CXCL16 in immunological liver injury...

on Zhonghua gan zang bing za zhi... April 2005
More articles like this..